Shionogi’s ensitrelvir has gained its first approval in Europe under the trade name of Zokovea, with the European Commission authorizing the antiviral for the post-exposure prophylaxis (PEP) of COVID-19.According to the Osaka-based drug maker, which announced the approval on September…
To read the full story
Related Article
- Shionogi’s Xocova Scores US FDA Nod for COVID-19 PEP
June 3, 2026
BUSINESS
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
- Santen to Seek Bankruptcy for Chinese Subsidiary
October 19, 2026
- Toho Invests in Keio Offshoot AdipoSeeds
October 19, 2026
- Amgen, JASSO Team Up on Obesity Research and Care
October 19, 2026
- Sanwa Kagaku to Resume Kumamoto Production on October 19
October 19, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





